MorphoSys AG and Integrated BioTherapeutics Provide Update Regarding USAMRIID Biodefense Project

Published: Jul 16, 2008

Martinsried/Munich, Germany, and Frederick, MD, USA, July 15, 2008 - AbD Serotec, a division of MorphoSys AG, announced today that its customer, US-based Integrated BioTherapeutics Inc. (IBT), has received a five-year, NIH research grant to develop human antibody therapeutics against staphylococcal enterotoxin B, a bacterial-derived toxin from Staphylococcus aureus.

The project is a continuation of a biodefense-related project initiated by USAMRIID, an organization of the U.S. Army Medical Research and Materiel Command, in September 2006 using AbD Serotec's custom monoclonal antibody services. Under the terms of the agreement, IBT will use a selection of HuCAL-based antibodies originally generated by AbD Serotec against staphylococcal eneterotoxin B in in vitro and in vivo experiments to identify lead neutralizing candidates and is expected to order additional antibody material as well as other services offered by AbD Serotec. Financial details of the agreement were not disclosed.

Staphylococcal enterotoxins are involved in a variety of human pathologies ranging from hospital and community-acquired infections, sepsis, toxic shock syndrome, to atopic dermatitis. Staphylococcal enterotoxin B is also considered as a potential agent of bioterrorism. Currently no vaccines or immunotherapeutics are available against staphylococcal toxins or S. aureus infections. The research collaboration between IBT and AbD Serotec follows a novel paradigm in the fight against these pathogens by targeting toxins released by bacteria which can distract the immune system and cause massive and even fatal damage.

"This grant allows us to continue a very promising project initiated by USAMRIID and AbD Serotec," said Dr. M. Javad Aman, President and CSO of IBT, "IBT is extremely pleased to have access to AbD's unique technology for developing antibodies with therapeutic potential in this important medical area."

"Today's news marks yet another promising development of a pre-existing customer relationship of AbD Serotec," comments Dr. Achim Knappik, Head of R&D at AbD Serotec. "We look forward to working with Integrated BioTherapeutics on this promising project in the field of infectious diseases which is an interesting research market for AbD Serotec."

About AbD Serotec: AbD Serotec is the research antibody division of MorphoSys, one of the world's leading human antibody technology companies with sales offices in Germany (Munich), the U.S. (Raleigh, NC), the U.K. (Oxford) and France. AbD Serotec's comprehensive product catalog comprises more than 10,000 research antibodies and immunology reagents guaranteed to perform to specification, with the majority in stock for next-day shipping. Custom monoclonal antibodies for research applications can be generated in just 8 weeks using fully recombinant HuCAL technology from MorphoSys. Additionally, AbD Serotec offers ISO-certified large-scale antibody production and a range of customized services including antibody conjugations for end-users and OEM customers. A comprehensive metasearch of the entire AbD Serotec range of ready-made antibodies can be performed at

About Integrated BioTherapeutics Inc.: Integrated BioTherapeutics Inc. (IBT) is a privately owned emerging research based company based in Germantown, Maryland, US. IBT's mission is to develop specific vaccines and immunotherapeutics against several emerging infectious diseases and agents of bioterrorism. Beside monoclonals antibodies against the biowarfare agent SEB, IBT is developing multivalent vaccines targeting various components of S. aureus bacteria as well virus-like particle based vaccines against Ebola and Marburg viruses two of the deadliest viruses known to man.

Back to news